Study identifier:D5130N00010
ClinicalTrials.gov identifier:NCT01276275
EudraCT identifier:N/A
CTIS identifier:N/A
A pharmacoepidemiological study to examine patient characteristics, drug utilization pattern and crude incidence rates of selected outcomes in new users of ticagrelor, clopidogrel and prasugrel in national Swedish registries
Bleeding ,arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea, gout
-
No
Risk of selected safety events
All
7200
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Mar 2016 by AstraZeneca
AstraZeneca
-
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time. A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
Location
Location
Stockholm, Sweden
Arms | Assigned Interventions |
---|---|
Exposure Group 1 First time users of ticagrelor | Drug: Risk of selected safety events First time users of ticagrelor, clopidogrel and prasugrel, respectively |
Exposure Group 2 First time users of clopidogrel | Drug: Risk of selected safety events First time users of ticagrelor, clopidogrel and prasugrel, respectively |
Exposure Group 3 First time users of prasugrel | Drug: Risk of selected safety events First time users of ticagrelor, clopidogrel and prasugrel, respectively |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.